1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections - Drugs In Development, 2022, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 12 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.
Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chlamydia Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chlamydia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chlamydia Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Chlamydia Infections - Overview
- Chlamydia Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Chlamydia Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chlamydia Infections - Companies Involved in Therapeutics Development
- Chlamydia Infections - Drug Profiles
- Chlamydia Infections - Dormant Projects
- Chlamydia Infections - Product Development Milestones
- Featured News & Press Releases
- Mar 31, 2022: Evofem presents positive encore data in sexually transmitted infections impacting women at the 2022 Academy of Managed Care Pharmacy Annual Meeting
- Mar 04, 2022: Evofem completes enrollment in EVOGUARD Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women
- Feb 09, 2022: FDA awards QIDP designation for prevention of chlamydia to Evofem Biosciences
- Jan 04, 2022: Evofem Biosciences to present at H.C. Wainwright BioConnect Conference
- Dec 21, 2021: Eurocine Vaccines resolves on scientific advice with the Swedish Medical Products Agency ahead of clinical trial application
- Dec 01, 2021: Eurocine Vaccines Chlamydia vaccine candidate elicits both antibody and T cell responses
- Nov 30, 2021: Evofem Biosciences announces successful type C meeting with FDA for STI prevention product candidate
- May 17, 2021: New data on EVO100 for the prevention of chlamydia and gonorrhea in women to be presented at ISPOR 2021
- Mar 31, 2021: Eurocine Vaccines initiates process development of the vaccine candidate against chlamydia
- Mar 16, 2021: Evofem Biosciences announces publication in American Journal of Obstetrics and Gynecology of AMPREVENCE study of EVO100 for chlamydia and gonorrhea prevention
- Feb 25, 2021: Eurocine Vaccines confirms good immunological effect in preclinical study with the chlamydia vaccine candidate
- Dec 30, 2020: Eurocine Vaccines advances the development of commercial manufacturing method and updates time plan
- Dec 30, 2020: Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate
- Dec 22, 2020: Evofem Biosciences to participate in Medicaid National Drug Rebate Program for Phexxi effective January 1, 2021
- Dec 21, 2020: Evofem Biosciences to present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Chlamydia Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Chlamydia Infections - Pipeline by Abera Bioscience AB, 2022
- Chlamydia Infections - Pipeline by Abivax SA, 2022
- Chlamydia Infections - Pipeline by Aeterna Zentaris Inc, 2022
- Chlamydia Infections - Pipeline by BlueWillow Biologics Inc, 2022
- Chlamydia Infections - Pipeline by Erganeo, 2022
- Chlamydia Infections - Pipeline by Eurocine Vaccines AB, 2022
- Chlamydia Infections - Pipeline by Evofem Biosciences Inc, 2022
- Chlamydia Infections - Pipeline by Genetic Immunity Inc, 2022
- Chlamydia Infections - Pipeline by Lead Discovery Center GmbH, 2022
- Chlamydia Infections - Pipeline by Merck & Co Inc, 2022
- Chlamydia Infections - Pipeline by Microbiotix Inc, 2022
- Chlamydia Infections - Pipeline by QureTech Bio AB, 2022
- Chlamydia Infections - Pipeline by Sanofi, 2022
- Chlamydia Infections - Pipeline by Traccine Pharmaceuticals, 2022
- Chlamydia Infections - Pipeline by Vault Pharma Inc, 2022
- Chlamydia Infections - Pipeline by Vaxine Pty Ltd, 2022
- Chlamydia Infections - Pipeline by Yaso Therapeutics Inc, 2022
- Chlamydia Infections - Dormant Projects, 2022
List of Figures
- Number of Products under Development for Chlamydia Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abera Bioscience AB
- Abivax SA
- Aeterna Zentaris Inc
- BlueWillow Biologics Inc
- Erganeo
- Eurocine Vaccines AB
- Evofem Biosciences Inc
- Genetic Immunity Inc
- Lead Discovery Center GmbH
- Merck & Co Inc
- Microbiotix Inc
- QureTech Bio AB
- Sanofi
- Traccine Pharmaceuticals
- Vault Pharma Inc
- Vaxine Pty Ltd
- Yaso Therapeutics Inc
